Chapter 24 / Rescue, Crisis, Inspection, and Leadership Judgment / Paid beta preview

Chapter 24: Regulatory Interactions and Inspections

How to manage regulatory interactions and inspections through truthful evidence and disciplined response. ## When External Scrutiny Arrives RESP-640 had moved from diagnosis to action. Safety follow-up had accelerated. Interim participant-protection measures were under accountable review. Amendment planning was active. Site communication was controlled. Governance had documented what was known, unknown, decided, and still pending. Then Thomas Gallagher received the email everyone knew might come. A regulatory authority had questions about RESP-640's safety signal, amendment chronology, protocol deviations, sponsor oversight of the CRO, and participant communication. An inspection might follow. A regulatory authority, sometimes called a health authority, is a government body responsible for oversight of medicines, clinical trials, or related public-health responsibilities. A regulatory interaction can be a meeting, written question, information request, submission, safety update, amendment communication, inspection communication, or commitment follow-up. A submission is a formal package or communication sent to an authority. A notification is a required or expected communication of information. Lauren Brooks felt the old PM reflex rise: gather everything, schedule everyone, answer fast. Thomas slowed her down. "Fast is good," he said. "Controlled is better. Regulators do not need our panic. They need the truth, the evidence, and the accountable owners." Grace Kim added the inspection version of the same lesson. "Inspection readiness is not making the file pretty," she said. "It is being able to reconstruct trial conduct from records, people, systems, and decisions." ## The INSPECT Frame Thomas and Grace gave Lauren a frame: | Letter | Meaning | PM Question | |---|---|---| | I | Information Known | What did the sponsor know, when, and from what evidence? | | N | Notification And Reporting | What had to be reported, to whom, by when, and by whom? | | S | Source And Records | Where is the evidence, and is it complete, traceable, and retrievable? | | P | Participant Protection | How were current and future participants protected? | | E | Explanation Discipline | Can the team explain decisions without speculation or defensiveness? | | C | Corrective Actions | What was corrected, prevented, monitored, or escalated? | | T | Team Roles | Who speaks, who supports, and who must not improvise? | The frame reminded Lauren that an inspection or regulatory question is not a performance. It is an evidence test. An inspection is a regulatory authority review of trial conduct, records, systems, and compliance. Inspection readiness is the ongoing ability to explain and evidence how the trial was conducted. Inspection conduct is the live management of the actual inspection process. An audit is generally an independent quality assessment, often internal or sponsor/vendor-directed. Audits can support readiness, but an audit is not the same as a regulatory inspection. ## Regulatory Interaction Versus Inspection RESP-640 had both regulatory interaction risk and inspection risk. They overlap, but they are not identical. | Event | Plain Meaning | PM Support | |---|---|---| | Information request | Authority asks for clarification or evidence | Track request, owners, evidence, review, deadline | | Protocol amendment submission | Sponsor submits proposed protocol change where required | Coordinate inputs, dependencies, version control, timelines | | Safety report or safety update | Safety information sent under applicable requirements | Support chronology and document flow with Safety/PV and Regulatory | | IRB/IEC communication | Ethics body receives required or relevant information | Track approved materials, site status, and participant communication evidence | | Regulatory meeting | Planned discussion with authority | Prepare agenda inputs, minutes, commitments, follow-up tracker | | Inspection | Authority reviews conduct, records, systems, and compliance | Support Quality/Regulatory-led inspection process | | Finding or observation | Inspector notes a concern or deficiency | Support root cause, evidence, CAPA tracking, and response logistics | Regulatory processes vary by country, product, trial type, and sponsor procedure. U.S. FDA terminology, European processes, and national authority expectations are not interchangeable. When the chapter uses FDA examples, it uses them as examples, not universal global rules. In the United States, FDA's Bioresearch Monitoring program, often called BIMO, includes inspections related to the conduct and reporting of FDA-regulated research. A GCP inspection focuses on whether Good Clinical Practice [ICH E6(R3)] responsibilities, records, participant protection, and data integrity were maintained. ## What We Knew, When We Knew It Caroline Whitaker helped Lauren build the chronology. It was not a spin document. It was a truth document. The team used the safety governance pathway to turn the details into operating choices the PM could assign, monitor, and escalate: Week 0: the accountable owner was Site/PV; known The The The signal was First worsening respiratory symptom report after dose escalation; evidence was Site AE record, source note; the PM response was to safety pathway initiated Week 1: the accountable owner was Nina/Samuel; known The The The signal was Similar reports emerged in two countries; evidence was Safety database, CRO escalation note; the PM response was to medical review requested Week 2: the accountable owner was PV/CRO/Quality; known The The The signal was Follow-up gaps identified; evidence was Safety reconciliation log; the PM response was to handoff issue escalated

...